Biogen's Key Variable: Its Neuroscience Pipeline

3/20/18

By William Meyers, SeekingAlpha

Biogen (NASDAQ:BIIB) is best known for its MS (multiple sclerosis) therapies. While Biogen is set to remain a major player in that setting, its future expansion will likely be in other neural diseases.

Q4 2017 results showed that process had already begun. Biogen’s newest therapy, Spinraza for SMA (spinal muscular atrophy), generated $363 million in revenue. Spinraza is licensed from Ionis (NASDAQ:IONS).

This article is primarily for investors who are thinking two to ten years into the future. Lately Biogen's stock price has dropped because one drug failed its Phase 2 trial and is being dropped, while Zinbryta has had to be withdrawn from the market not that long after getting its regulatory approvals.

Since companies are complex, and competition must be taken into account, identifying the key variables that determine future profitability is crucial to an analysis. In the case of Biogen, the key variable is the expansion of its neuroscience pipeline. It is highly likely that this will lead to strong profit growth over time, perhaps achieving the stated goal of becoming the "fastest growing large cap biotech."

READ FULL ARTICLE HERE